-- 
BioCancell Soars Most in 2 Months on FDA ‘Fast Track’ Status

-- B y   G w e n   A c k e r m a n
-- 
2011-10-04T14:47:58Z

-- http://www.bloomberg.com/news/2011-10-04/biocancell-surges-most-in-a-month-on-fda-fast-track-status.html
BioCancell Therapeutics Inc. jumped
the most in more than two months after it said the U.S.  Food and
Drug Administration  gave its BC-819 pancreatic-cancer treatment
“fast track” status.  The shares advanced 6.3 percent, the biggest gain since
Aug. 1, to 1.46 shekels at the 4:30 p.m. close in Tel Aviv,
giving the Jerusalem-based company a market value of 39 million
shekels ($10.7 million).  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  